{
    "2019-08-26": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study",
                "features": {
                    "keywords": [
                        "Olumiant",
                        "Primary Endpoint",
                        "Eczema",
                        "Study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-04-16",
                "original_text": "Lilly Receives U.S. FDA Approval for TaltzÂ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)",
                "features": {
                    "keywords": [
                        "Lilly",
                        "FDA Approval",
                        "Taltz",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}